LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

LLY

1,022.27

-0.86%↓

JNJ

203.44

-1.28%↓

ABBV

230.28

+1.77%↑

UNH

335.94

+2.03%↑

AZN

90.46

-0.12%↓

Search

Guardant Health Inc

Aperta

SettoreSettore sanitario

108.4 4.61

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

103.58

Massimo

107

Metriche Chiave

By Trading Economics

Entrata

7.2M

-93M

Vendite

33M

265M

Margine di Profitto

-34.965

Dipendenti

1,999

EBITDA

6.6M

-82M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

-12.38% downside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

4.7B

14B

Apertura precedente

103.79

Chiusura precedente

108.4

Notizie sul Sentiment di mercato

By Acuity

50%

50%

167 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Guardant Health Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

3 dic 2025, 23:21 UTC

Utili
Acquisizioni, Fusioni, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 dic 2025, 23:14 UTC

Acquisizioni, Fusioni, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 dic 2025, 22:01 UTC

I principali Market Mover

Costco Wholesale Reports Higher Monthly Sales

3 dic 2025, 21:38 UTC

Utili

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 dic 2025, 23:59 UTC

Discorsi di Mercato

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 dic 2025, 23:49 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

3 dic 2025, 23:49 UTC

Discorsi di Mercato

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 dic 2025, 23:49 UTC

Discorsi di Mercato

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 dic 2025, 23:13 UTC

Discorsi di Mercato

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 dic 2025, 23:10 UTC

Utili

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 dic 2025, 23:08 UTC

Discorsi di Mercato

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 dic 2025, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 dic 2025, 22:59 UTC

Acquisizioni, Fusioni, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

3 dic 2025, 22:45 UTC

Discorsi di Mercato

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 dic 2025, 22:20 UTC

Utili

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 dic 2025, 22:19 UTC

Utili

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 dic 2025, 22:17 UTC

Utili

Salesforce Working to Add Voice to Agentforce, CEO Says

3 dic 2025, 22:16 UTC

Utili

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 dic 2025, 22:15 UTC

Utili

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 dic 2025, 22:10 UTC

Acquisizioni, Fusioni, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 dic 2025, 22:09 UTC

Acquisizioni, Fusioni, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 dic 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

3 dic 2025, 21:50 UTC

Discorsi di Mercato

Basic Materials Roundup: Market Talk

3 dic 2025, 21:49 UTC

Utili

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:23 UTC

Utili

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 dic 2025, 21:19 UTC

Utili

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:06 UTC

Utili

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 dic 2025, 21:04 UTC

Utili

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 dic 2025, 21:04 UTC

Utili

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 dic 2025, 21:03 UTC

Utili

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Confronto tra pari

Modifica del prezzo

Guardant Health Inc Previsione

Obiettivo di Prezzo

By TipRanks

-12.38% in calo

Previsioni per 12 mesi

Media 92.84 USD  -12.38%

Alto 130 USD

Basso 60 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Guardant Health Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

20

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

38.86 / 47.41Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Bearish Evidence

A lungo termine

Bullish Evidence

Sentiment

By Acuity

167 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Guardant Health Inc

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research; and with ConcertAI to form first data-as-a-service that integrates clinical and tumor profiling data to accelerate cancer therapy research and development. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
help-icon Live chat